# Cedarburg Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cedarburg-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Grafton, US
- Website: www.cedarburgpharma.com
- Total disclosed funding: $11M
- Latest round: Series A (Feb 13, 2007)
- Investors on record: 2

## About

Cedarburg Pharmaceuticals focuses on providing comprehensive contract development and manufacturing services to the pharmaceutical and biotechnology sectors, specializing in drug discovery, development, and manufacturing.Founded in 1998 in Grafton, US, Cedarburg Pharmaceuticals offers CDMO services to the pharmaceutical industry. The company was acquired by Albany Molecular Research in April 2014 for USD 41.00 mn. No further changes in business strategy or subsidiaries have been noted.Cedarburg Pharmaceuticals specializes in a comprehensive range of services within the Contract Development and Manufacturing Organization (CDMO) sector, catering to the pharmaceutical and biotechnology industries. Their core product offerings include drug discovery, development, and manufacturing services across Small Molecules, Generic APIs, and Biologics. These solutions are designed to tackle the complexities of early drug development and streamline the entire process, from discovery through to Good Manufacturing Practice (GMP) manufacturing. Cedarburg serves a diverse clientele, including biopharma companies of all sizes, with a strong emphasis on collaboration and meeting the specific needs of their customers. The company's offerings are marketed and utilized in various geographical regions, including North America, Europe, and India, where they leverage local regulatory knowledge and scientific expertise.Cedarburg Pharmaceuticals generates revenue primarily through B2B transactions with its clients, including pharmaceutical and biotechnology companies that seek to outsource their drug development and manufacturing processes. The company's transaction structure typically involves partnerships where clients contract specific services ranging from drug discovery to GMP manufacturing. These partnerships enable clients to access Cedarburg's advanced technologies and scientific expertise on a project basis. While specific pricing plans for individual services are not detailed, the company's revenue is derived from these comprehensive service agreements that cater to the unique requirements of each client. Additionally, Cedarburg's flagship offerings are geared toward delivering high-quality, compliant products to enhance the speed and efficiency of bringing new therapies to market.Cedarburg Pharmaceuticals' recent acquisition will enable the firm to explore new product developments and enhance its service offerings in the CDMO space. The company is also expected to target expansion into new geographic regions and markets as it integrates with Albany Molecular Research. The recent funding from the acquisition will support these initiatives, allowing Cedarburg to leverage new resources and capabilities to enhance its product development and service delivery strategy.

## Funding rounds

- Series A, Feb 13, 2007, $3.5M — Houston Ventures
- Series A, Mar 3, 2004, $7M — Signet Healthcare Partners

## Investors

- Signet Healthcare Partners (https://capitalatlas.ai/funds/signet-healthcare-partners) — Series A
- Houston Ventures (https://capitalatlas.ai/funds/houston-ventures) — Series A